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Introduction: There is reasonable evidence that folic acid 5–10 mg per week leads to reduction in methotrexate
(MTX) toxicity in rheumatoid arthritis (RA). However, this is based on studies conducted with lower MTX dosage
than used currently. It is unclear whether higher doses of folic acid may be better in reducing toxicity.
Methods: This was a double-blind randomized controlled trial of 24 weeks duration. To be eligible, patients should have
rheumatoid arthritis (1987 American College of Rheumatology criteria), be 18–75 years of age, not be on MTX and have
active disease as defined by ‘Modified Disease Activity Score using three variables’ (DAS28(3)) > 3.2. MTX was started at 10
mg/week and escalated to 25 mg/week by 12 weeks. Folic acid was given at a dose of 10 mg (FA10) or 30 mg per week
(FA30). Co-primary endpoints were incidence of toxicity (undesirable symptoms and laboratory abnormalities) and change
in disease activity by 24 weeks. Intention-to-treat and per-protocol analyses were performed.
Results: Among 100 patients enrolled, 51 and 49 were randomized to FA10 and FA30 respectively. By 24 weeks, there
were 6 patient withdrawals in either group and mean(±SD) dose of MTX was 22.8 ± 4.4 and 21.4 ± 4.6 mg per week
(p = 0.1). Frequency of patients with undesirable symptoms was non-significantly lower by 7.4 % (95 % confidence interval
−27.4 to 12.7 %) in FA10 compared to FA30. There was also no difference in frequency of transaminitis (>Upper limit of
normal (ULN)) (42.6, 45.7 %, p = 0.7) or transminitis as per primary endpoint (>2xULN) (10.6, 8.7 %, p = 1.0) or cytopenias
(4.3, 4.3 %, p = 0.9). There was no difference in the primary end-point of occurrence of any adverse effect (symptom or
laboratory) in FA10 and FA30 (46.8, 54.3 %, p = 0.5). At 24 weeks, DAS28(3) declined in both groups by a similar extent
(−1.1 ± 1.0, −1.3 ± 1.0, p = 0.2) and ‘European League Against Rheumatism’ good or moderate response occurred in
56.9 and 67.4 % (p = 0.3).
Conclusions: Even with the high doses of MTX used in current practice, there was no additional benefit (or harm) of a
higher dose of folic acid (30 mg/week) over a usual dose (10 mg/week).
Trial Registration: Clinicaltrials.gov NCT01583959 Registered 15 March 2012Introduction
Soon after the discovery of folic acid in 1941, its chem-
ical analog and antifolate, aminopterin was developed
and used in rheumatoid arthritis (RA) [1]. It was quickly
supplanted by another analog, amethopterin, better
known as methotrexate (MTX), first used in RA in 1964
[2]. However, MTX came into regular use only after* Correspondence: varundhir@gmail.com
1Department of Internal Medicine, Postgraduate Institute of Medical
Education and Research, Chandigarh 160020, India
Full list of author information is available at the end of the article
© 2015 Dhir et al. This is an Open Access artic
(http://creativecommons.org/licenses/by/4.0),
provided the original work is properly credited
creativecommons.org/publicdomain/zero/1.0/pivotal controlled trials in the 1980s confirmed its effi-
cacy and long-term studies found it to have the highest
patient retention rate of all disease modifying anti-
rheumatic drugs (DMARDs) [3–6]. In the last two de-
cades, MTX has attained the status of gold standard and
is the anchor drug for RA, being used in nearly 80 % of
patients [7, 8]. However, withdrawals can occur in up to
30–50 % patients, mainly due to toxicity, thus limiting
its use and necessitating expensive and toxic therapies
[9, 10]. In a previous study, we found that patients with
adverse effects had higher disease activity, probably duele distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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toxicity and optimize the efficacy of MTX have received
increasing attention in the past few years [12, 13].
One evidence-based strategy to reduce toxicity is sup-
plementing with folic acid. There is reasonable proof
from three controlled trials, and many meta-analyses
that folic acid reduces the toxicity of MTX and the num-
bers of patients dropping out of treatment due to in-
tolerance [14–19]. Indeed, most major contemporary
guidelines currently recommend that folic acid supple-
mentation is used with MTX [20–22]; however, its use
remains controversial. First, there is controversy over
the optimum dose of folic acid. Although most reviews
and guidelines suggest a dose of 5–10 mg per week, this
is based on insufficient evidence [22, 23]. Indeed, the
only study that compared different doses of folic acid
was done 20 years ago with MTX limited to 9–10 mg
per week [15]. With the current use of higher MTX
doses, such as 25 mg per week, it is unclear whether the
dose of folic acid should be increased. Second, there is
controversy over the effect on the efficacy of MTX. A
large controlled trial did find prescription of slightly
higher doses of MTX to achieve similar efficacy in the
folic acid group [16]. In addition, some studies have sug-
gested a negative effect on efficacy [24]. Thus, our study
was planned to answer two questions. First, will a higher
folic acid dose (30 mg per week) reduce the toxicity of
MTX compared to a lower dose (10 mg per week) in
RA? Second, will a higher folic acid dose lead to blunt-
ing of the efficacy of MTX compared to a lower dose?
Methods
Study design
This was a pragmatic double-blind parallel-group random-
ized controlled trial. This study was conducted in a single
center and patients were enrolled between August 2012
and August 2013. This study protocol was approved by
the Institutional Ethics Committee at the Postgraduate In-
stitute of Medical Education and Research (PGIMER). The
study was conducted according to current regulations in
the International Conference on Harmonization guidelines
and the principles of the Declaration of Helsinki. Written
informed consent was obtained from all the patients in-
cluded in this study. The trial, Folic acid in variable
doses in rheumatoid arthritis (FOLVARI), is registered
(Clinicaltrials.gov NCT01583959, date of registration
15 March 2012).
Participants
Participants enrolled into the study were patients with
RA, who were 18–75 years of age, fulfilled the American
College of Rheumatology 1987 revised criteria, and had
active disease (defined as modified disease activity score
using three variables (DAS28(3)) >3.2) [25, 26]. Weexcluded patients who were currently receiving MTX or
had received it in the last 8 weeks or were currently on
folic acid supplements. Patients with contraindication(s)
to methotrexate were also excluded. This included pa-
tients who were breast feeding or pregnant; had chronic
liver or kidney disease; had cytopenia (below the lower
limit of normal) or transaminitis (aminotransferases
above the upper limit of normal); had active infection,
including but not restricted to HIV, or hepatitis B or C,
or active tuberculosis.
Study treatments
All patients were started on oral MTX at a dose of 10
mg per week. The dose of MTX was escalated by 2.5 mg
every 2 weeks, subject to the patient not achieving re-
mission nor having toxicity (evaluated every 8 weeks),
till a maximum dose of 25 mg per week was reached
(see Study procedures). Patients were randomized in a
ratio of 1:1 to receiving folic acid at a dose of 10 mg/
week (FA10 group) or 30 mg/week (FA30 group) for 24
weeks. For this purpose, weekly packs consisting of six
identical tablets were given to the patients, one tablet
from a packet to be taken every day of the week, except
the day when they took MTX. The tablets in these packs
consisted of either two tablets of 5 mg folic acid (and
four tablets of identical placebo) or six tablets of 5 mg
folic acid. Thus, in the former group, patients could be
taking the two tablets of folic acid on any of the days of
the week. At 16 weeks, at the treating physician’s discre-
tion, another DMARD (leflunomide, hydroxychloro-
quine, or sulfasalazine) could be started (in the case of
poor response). In addition, participants could receive a
total of three intramuscular injections of depot methyl-
prednisolone acetate 80 mg during the course of the
study at the treating physician’s discretion (excluding the
last 8 weeks of the study period).
Study outcomes
The primary outcome was the occurrence of MTX
toxicity during 24 weeks. This included undesirable
symptoms experienced by patients (evaluated using a
questionnaire) and laboratory abnormalities (cytopenia
or elevation of transaminases). Cytopenia was defined
as a platelet count <100 × 106/L or white blood counts
<4 × 106/L. Elevation of transaminases was defined as
values more than twice the upper limit of normal (nor-
mal = 40 IU/L). The co-primary outcome was change
in disease activity at 24 weeks. Secondary outcomes
were change in the level of red blood cells (RBC) (and
serum) folic acid at 24 weeks (from baseline) and
change in the functional status of patients (assessed using
the Indian health assessment questionnaire (HAQ)) [27].
Other outcomes assessed were change in serum matrix-
metalloproteinase-3 (MMP-3) levels at 24 weeks (from
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interleukin-6 and interleukin-10 (in some patients).
Study procedures
At baseline and every visit (8 weekly), all patients were
examined and joint counts performed by a single phys-
ician (VD), who remained blinded to their group. The
DAS28(3) was calculated using the formula: (0.56*√
(tender joints) + 0.28*√ (swollen joints) + 0.70*Ln
(erythrocyte sedimentation rate)) *1.08 + 0.16 [26].
At baseline patients underwent investigations includ-
ing chest and hand radiography, complete blood counts,
erythrocyte sedimentation rate (ESR), renal and liver
function tests, rheumatoid factor and anti-citrullinated
peptide assay (ACPA). MTX was started at a dose of 10
mg per week, and patients were instructed to increase
the dose by 2.5 mg after every two doses (weeks) till
their next visit. Thus, at the first follow up visit (8
weeks), most patients were on a dose of 17.5 mg per
week, whereas by the second visit (16 weeks) most were
on 25 mg per week. A decision to continue with es-
calation of MTX was made based on disease activity
(remission - yes or no) and laboratory abnormalities
(none or mild, moderate or severe). Further escalation of
MTX was stopped in patients with remission (DAS28(3)
≤2.6) or moderate laboratory abnormalities (platelet
count 90–100 × 106/L, white blood count 3.5–4.0 × 106/L,
or transaminases more than twice the upper limit of nor-
mal). MTX was stopped completely in patients with severe
laboratory abnormalities (platelet count <90 × 106/L,
white blood count <3.5 × 106/L, or transaminases more
than three times the upper limit of normal). Patients with
moderate or severe laboratory abnormalities were called
earlier at 2–4 weeks and re-evaluated. When abnormality
was resolved, MTX, or its escalation, was restarted. A pa-
tient was suspected to have pulmonary toxicity in the
event of a cough lasting longer than 2 weeks that was
non-responsive to antibiotics and associated with breath-
lessness or any respiratory failure.
At every visit, patients completed a questionnaire that
contained a list of undesirable symptoms that instructed
them to “Tick symptoms which are new AND tempor-
ally related to the day on which you take methotrexate”.
The list included symptoms of nausea and vomiting, diz-
ziness, fatigue and malaise, uneasiness, anorexia, dysgue-
sia, headache, skin rash and itching, diarrhea and oral
ulcers. In addition, blood counts and transaminase levels
were assessed at every visit. At baseline and 24 weeks
patients were administered the Indian HAQ [27]. At
every study visit a blood sample was collected in a cit-
rate and plain vacutainer for ESR and serum separation
(stored at −80 °C), respectively. RBC and serum folate
levels were measured at baseline and 24 weeks, using
chemiluminescent immunoassay on ADVIA Centaur(Siemens Healthcare Diagnostics Inc, IL, USA). To de-
fine low/deficient serum levels of folate, we used two
cutoffs - 3 ng/ml (Institute of Medicine, NIH) and 4 ng/ml
(World Health Organization (WHO) technical consult-
ation) [28, 29]. Low RBC folate levels were defined using
cutoffs of 140 ng/ml (Institute of Medicine, NIH) and 151
ng/ml (WHO technical consultation). Levels of MMP-3
were measured using ELISA (Human Total MMP-3 Duo-
Set, RnD). In a few patients, serum levels of TNFα and
interleukin-6 were determined using cytokine bead array
(BD Cytometric Bead Array (CBA), Becton Dickinson, La
Jolla, CA, USA).
Randomization and blinding
This was a double-blind study in which the participants,
physician assessor and drug dispensing personnel were
blinded to the dose of folic acid being administered. Ini-
tially, weekly packets consisting of six tablets - either
two tablets of 5 mg folic acid (and four tablets of identi-
cal placebo) or six tablets of 5 mg folic acid were pre-
pared and put into separate boxes. A colleague coded
boxes as A or B, and kept the code secret till completion
of the analysis. Randomization codes for individual pa-
tients (A or B) were generated using an online random
number generator available on the website randomiza-
tion.com (http://www.randomization.com, seed 20243)
using permuted-block randomization (variable-sized blocks
of 4, 6 and 8). Allocation concealment was maintained
using serially numbered opaque envelopes and identical
weekly packs and tablets.
Statistical analysis
We assumed the frequency of toxicity (symptoms or la-
boratory) as 60 % in the 10-mg folic acid group, and esti-
mated that it would halve to 30 % in the folic acid 30-mg
group. Keeping the alpha error probability of 0.05 and
power of 80 %, using a two-sided test we estimated the
sample size required to be 48 in each group (G*Power 3.1)
[30]. Comparison of continuous variables was done using
the independent t test and categorical variables using the
chi squared (χ2) or Fisher’s exact test, using SPSS (Version
20, SPSS Inc., Chicago, IL, USA). Both intention-to-treat
and per-protocol analyses were performed. Graphical illus-
trations were prepared using GraphPad Prism (version
5.00, GraphPad Software, San Diego, CA, USA).
Results
A total of 130 patients with rheumatoid arthritis were
assessed for eligibility, resulting in the inclusion of 100 pa-
tients (Fig. 1). Of these, 51 were randomized to receive
folic acid at a dose of 10 mg per week (FA10), while 49 pa-
tients were randomized to 30 mg per week (FA30). These
two groups did not have any significant differences in
demographic and baseline characteristics (Table 1). By 24
130 patients screened 
for inclusion 
Group FA10 
Folic acid 10 mg/week 
Patients allocated N=51  
All received Rx 
Group FA30 
Folic acid 30 mg/week, 
Patients allocated N=49  
 All received Rx 
100 patients 
randomized 
Completed 24 weeks, n=45 
Adverse effects analysis: 
N=47 (at least 1 FU) 
Efficacy analysis, N=51 
Completed 24 weeks, n=43 
Adverse effects analysis: 
N=46 (at least 1 FU) 
Efficacy analysis, N=49 
6 did not complete  
(5 Lost to follow up, 1 
suspected lung Toxicity) 
6 did not complete  
(6 Lost to follow up) 
30 patients excluded 
25 Not eligible 
5 No consent 
Fig. 1 Flow chart showing flow of participants in the study. Rx
treatment, FU follow up
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Out of these, one patient (FA10 group) was withdrawn
due to suspected pulmonary toxicity, and the remaining
patients were lost to follow up. Mean (± SD) weekly dose
of methotrexate at 24 weeks was not significantly different
in FA10 and FA30 (22.8 ± 4.4, 21.4 ± 4.6 mg, p = 0.1). At
24 weeks, 38 and 29 patients in FA10 and FA30 were on
an MTX dose of 25 mg per week (p = 0.1). The common
reason for not reaching a dose of 25 mg/week was adverseTable 1 Baseline characteristics and demographics of patients inclu
Mean ± SD (except where stated otherwise) Folic acid 10 mg pe
N = 51
Age, years 44.8 ± 10.0
Female, number (%) 44 (86)
Duration of disease, years 4.4 ± 4.1
Disease activity score (DAS28(3)) 5.8 ± 0.9
Tender joint count, 0–28 11.0 ± 4.8
Swollen joint count, 0–28 5.1 ± 3.3
HAQ, 0–3 1.1 ± 0.5
Hemoglobin, g/dl 10.8 ± 1.7
Serum albumin, g/dl 4.0 ± 0.5
ESR, mm, first hour 65.4 ± 33.2
Rheumatoid factor-positive, number (%) 42 (84)
ACPA-positive, number positive/number tested (%) 45/48 (94)
DAS28(3) modified disease activity score using three variables, HAQ health assessmeeffects (Table 2). After 16 weeks of MTX monotherapy,
29 patients had been started on an additional DMARD.
Leflunomide was added in 28 patients (18 and 10 in
FA10 and FA30, p = 0.1) and sulfasalazine in one pa-
tient (FA10 group).
Primary outcome
There was no difference in the frequency of patients
who had undesirable symptoms related to MTX in either
of the groups. The most common symptoms were nau-
sea, dizziness and uneasiness. The frequency of patients
who experienced any undesirable symptom was 7.4 %
lower (but not significantly: CI −27.4, 12.7) in FA10
compared to FA30. Similarly, the frequency of patients
with nausea was 15.7 % lower (but not significantly: CI
−33.9, 2.5) in FA10 (Table 3). There was no difference
between groups in the frequency of patients who devel-
oped transaminitis or cytopenia. Even on analyzing only
those patients who received 25 mg of MTX per week,
there was no difference (data not shown). There was no
difference between the groups in the composite end-
point of occurrence of any adverse effect (symptoms or
laboratory measures), observed in 46.8 and 54.3 % (p =
0.5) of the FA10 and FA30 groups, respectively (Table 3).
There was no significant difference in mean (± SD)
change in DAS28(3) in FA10 (−1.1 ± 1.0) and FA30 (−1.3 ±
1.0) (p = 0.2). At the 8-, 16- and 24-week time points, mean
(± SD) DAS28(3) (and its components) was not signifi-
cantly different between groups (Fig. 2). At 24 weeks, a
good or moderate response according to the European
League Against Rheumatism (EULAR) criteria occurred
in 56.9 and 67.4 % patients in FA10 and FA30, respect-
ively (p = 0.3). Even on per-protocol analysis, there was
no difference in any of the efficacy measures (Fig. 2).ded in the study
r week (FA10) Folic acid 30 mg per week (FA30) P value
N = 49
43.8 ± 11.9 0.7
41 (84) 0.8
5.2 ± 5.1 0.4
5.7 ± 0.9 0.9
11.2 ± 5.2 0.8
5.6 ± 3.6 0.5
1.1 ± 0.5 0.7
10.9 ± 2.0 0.7
3.9 ± 0.6 0.7
59.5 ± 30.0 0.3
35 (71) 0.2
39/43 (91) 0.6
nt questionnaire (Indian), ACPA anti-citrullinated protein antibody
Table 2 Reasons for patients within both groups not reaching a
dose of 25 mg per week of methotrexate
Folic acid 10 mg
per week (FA10)
Folic acid 30 mg
per week (FA30)
P value
Adverse effects 4 8 0.2
Achieved remission 2 4 0.2
Lost to follow up 5 6 0.7
No reason determined 2 2 1.0
Total 13 20 0.1
Results are presented as number of patients
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There was a significant increase in the serum folate
levels in both groups from baseline to 24 weeks (mea-
sured in 68 patients); the level at 24 weeks in FA30 was
almost twice that of FA10 (Fig. 3). However, there was
no significant change in RBC folate levels in either of
the groups. The HAQ score declined significantly and
similarly in both groups (−0.3 ± 0.5, −0.4 ± 0.4, p = 0.27)
(Fig. 3).
Other outcomes
Pulmonary toxicity due to MTX was suspected in two
patients (both in FA10), who had an unresponsive cough
with dyspnea, one of whom one was restarted on MTX.
Herpes zoster occurred in three patients during theTable 3 Number (percent) of patients in the two groups who exper
Adverse effects/toxicity Folic acid 10 mg per week (F
N = 47a
Undesirable symptoms
Any undesirable symptom 18 (38.3)




Loss of appetite 2 (4.3)
Dysguesia 1 (2.1)
Headache 0 (0)
Oral ulcers 0 (0)
Laboratory abnormalities
Transaminitis (more than ULN) 20 (42.6)
Transaminitis (more than 2 × ULN) 5 (10.6)
Cytopenia 2 (4.3)
Primary outcomeb 22 (46.8)
Other adverse effects
Suspected pulmonary toxicity 2 (4.3)
Herpes zoster 2 (4.3)
Results are presented as number (percent) of patients. aIncluded only those patient
cytopenia or transminases elevated more than twice the upper limit of normal (ULNstudy (Table 3). There was a significant decline in the
serum MMP-3 levels at 24 weeks compared to baseline
in both groups (p = 0.001), however, there was no sig-
nificant inter-group difference at 24 weeks (Fig. 3).
There was no significant change in the level of TNFα or
interleukin-6 in any group and no difference between
groups (measured in 15 patients, not shown).
Folate levels at baseline
At baseline, low serum folate levels (in 95 patients in
whom these were available) when defined using a value
of <4 ng/ml were found in 9 patients (9.5 %) and in 4
patients (4.2 %) when defined using a value <3 ng/ml.
Low RBC folate levels (in 85 patients in whom these
were available), when defined using a value <151 ng/ml
was found in 7 patients (8.2 %); 5 patients (6 %) were iden-
tified using a value of <140 ng/ml. Undesirable symptoms
were significantly associated with low baseline serum levels
of folate (for both cutoffs) (relative risk = 2.1 (CI 1.3–3.3))
but not with low RBC folate levels using either cutoff.
However, there was no significant association between ei-
ther low serum, or low RBC levels and the occurrence of
transaminitis (>2 × ULN), cytopenia, or the composite pri-
mary endpoint. There was no correlation between the fol-
ate (serum or RBC) levels at baseline and the number of
adverse effects (symptoms or laboratory measurements)
(data not shown). Furthermore, even on excluding patientsienced methotrexate toxicity at any time during the study
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Fig. 2 Change in disease activity (DAS 28(3)) and EULAR response criteria achieved by 24 weeks in the two groups. The p value was not
significant at any time point. DAS 28(3) modified disease activity score using three variables, EULAR European League Against Rheumatism, FA10
group in which folic acid 10 mg per week was given, FA30 group in which folic acid 30 mg per week was given
Dhir et al. Arthritis Research & Therapy  (2015) 17:156 Page 6 of 9with low serum or RBC folate, there was no difference be-
tween groups in the primary endpoint.
Discussion
Although, major guidelines and reviews recommend folic
acid at a dose of 5 to 10 mg per week with MTX, toameliorate toxicity, they acknowledge that ‘the evidence
base is insufficient to determine the optimum dose’ and
there may be ‘potential need for higher dosages, with the
currently higher dosed methotrexate’ [22, 23]. Indeed, des-
pite four randomized controlled trials on folic acid supple-





































































Fig. 3 Change in mean Indian health assessment questionnaire (HAQ) scores, folic acid levels and matrix metalloproteinase-3 (MMP-3) in the two
groups; *** p <0.001, *p <0.05. FA10 group in which folic acid 10 mg per week was given, FA39 group in which folic acid 10 mg per week was given
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folic acid supplementation with MTX was restricted to the
effect of low doses of folic acid (≤7 mg per week) [19].
This study, a randomized controlled trial, found no in-
cremental benefit (further reduction of toxicity) with a
higher dose of folic acid (30 mg per week) compared to
the usual dose (10 mg per week). This was similar to the
previous trial by Morgan et al. that compared 27.5 and
5.0 mg per week of folic acid [15]. However, there are
important differences between these studies apart from
the slightly different folic acid doses. The latter was con-
ducted 20 years ago and the MTX dose was 9–10 mg
per week compared to the mean dose of MTX, which
was 21–22 mg in this study. That study used toxicity
scores, whereas we have compared presence of symp-
toms, laboratory abnormalities and infections/lung tox-
icity separately. Although our study had small numbers,
the confidence intervals suggest that higher-dose folic
acid is unlikely to have a significant benefit in reducing
either symptoms or laboratory abnormalities. However,
it is difficult to interpret differences in the occurrence of
uncommon toxicities such as pulmonary and herpes zos-
ter that were higher, but not significantly so, in the 10-
mg folic acid group.
Controversy remains on the effect of folic acid on the ef-
ficacy of MTX. Although no previous controlled trial has
demonstrated this, the largest trial conducted showed a
greater requirement for MTX in the folic acid group [16].
Another study, a post-hoc analysis of two different studies,
found lower responses in the population supplementedwith folic acid [24]. Also a study comparing different co-
horts at different times periods found higher doses of
MTX being used after folic acid fortification of food [31].
The latter two studies were inherently limited due to com-
parison of different populations (or across time). Our
study cannot answer this question, as it lacked a placebo
arm due to ethical considerations. However, our results
suggest that any reduction in efficacy (if it occurs) does
not have a dose–response effect. Indeed, we found a simi-
lar decline of DAS28(3) in both groups. This is further
borne out by similar MTX doses in both groups and
addition of a DMARD in similar numbers at 16 weeks.
Additionally, decline in HAQ score, withdrawals in both
arms and MMP-3 levels in both groups by 24 weeks were
similar. Morgan et al. used discrete measures of activity,
such as the joint index for tenderness or swelling and grip
strength, and also found no difference between 5 mg and
27.5 mg folic acid per week [15].
We suggest that lack of any incremental benefit (i.e.,
higher folic acid leading to reduced toxicity) may be re-
lated inherently to the mechanism of action of folic acid.
MTX has been shown to reduce intracellular folate
levels in the liver, lymphocytes and RBCs [32, 33]. In
addition, folate depletion is a risk factor for MTX tox-
icity [15]. Our results support the postulation that folic
acid merely serves to correct the intracellular folate defi-
ciency with MTX [15]. Indeed, the observed threshold of
benefit of folic acid with MTX toxicity, can be explained
by a dose of 5–10 mg per week to adequately correct
this deficit. In addition, the lack of a dose–response
Dhir et al. Arthritis Research & Therapy  (2015) 17:156 Page 8 of 9effect of folic acid supplementation on efficacy does not
support the alternate postulation, that folic acid reduces
toxicity by directly antagonizing the action of MTX [34].
It is pertinent to mention differences with folinic acid.
Many studies found high doses of folinic acid to affect
MTX efficacy [35]. This may be related to two inherent
differences from folic acid. One, folinic acid is a reduced
and active folate that bypasses dihydrofolate reductase
enzyme to provide the one-carbon folates necessary (un-
like folic acid). Second, the transmembrane transport of
folinic acid uses reduced folate carrier (RFC), that dir-
ectly competes with MTX (folic acid uses a different
channel - folate receptors) [36].
A limitation of our study is that some patients were
started on another DMARD in the last 8 weeks (mainly
leflunomide). This could have been responsible for some
episodes of transaminitis and symptoms. However, we spe-
cifically asked patients to indicate adverse effects related
to the timing of MTX use, and the results remained the
same even after excluding the last 8 weeks. One of the
strengths of this study is that it was done in a country
(India) where there is no folic acid fortification program
that may have confounded results in another country with
such a program. We decided against including a group of
patients on placebo (no folic acid supplementation) based
on existing evidence at the time of planning the study.
However, it would certainly have helped better clarify any
effect on efficacy. The choice of dosage of folic acid in this
study was partly related to logistics - only 5-mg tablets
(and not 1-mg tablets) are marketed in our country. One
valid criticism is that a dose of 5 mg once weekly (instead
of twice weekly) may have been more appropriate as a
comparator, as the former is more commonly used in
many setups [22]. Also, in our study, patients in the 10-
mg group could have taken their folic acid 5 mg tablets on
any two days of the week except on the MTX day (ran-
domly as they were given six identical tablets). Finally, our
protocol of avoiding co-administration of folic acid on the
same day as MTX, is not evidence-based, but has been
suggested in certain guidelines and reviews [20, 23].
Conclusions
We believe our study adds to the evidence on how best
to supplement folic acid with MTX. Our results concur
with the conclusions of many guidelines or reviews that
5–10 mg folic acid is enough, and higher doses do not
offer any additional benefit even with the contemporary
doses of MTX used in RA (such as 25 mg per week).
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